TriSalus Life Sciences, Inc. (NASDAQ:TLSI) Receives Average Recommendation of “Hold” from Analysts

TriSalus Life Sciences, Inc. (NASDAQ:TLSI) has been given an average rating of “Hold” by the five ratings firms that are covering the firm, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and three have given a buy rating to the company. The average 12-month price objective among brokerages that have covered the stock in the last year is $8.6667.

A number of analysts have recently issued reports on the stock. HC Wainwright started coverage on shares of TriSalus Life Sciences in a report on Wednesday, September 9th. They set a “buy” rating and a $11.00 price target for the company. Weiss Ratings reiterated a “sell (e+)” rating on shares of TriSalus Life Sciences in a research report on Friday, August 7th. Wall Street Zen upgraded TriSalus Life Sciences from a “sell” rating to a “hold” rating in a research report on Sunday, August 23rd. Finally, Zacks Research upgraded TriSalus Life Sciences to a “hold” rating in a research report on Thursday, September 10th.

TriSalus Life Sciences Trading Up 0.2%

Shares of TLSI opened at $4.78 on Wednesday. The company has a current ratio of 5.35, a quick ratio of 4.97 and a debt-to-equity ratio of 5.05. TriSalus Life Sciences has a 12-month low of $2.20 and a 12-month high of $7.95. The firm has a 50-day moving average price of $4.78 and a 200 day moving average price of $4.32. The firm has a market capitalization of $294.35 million, a P/E ratio of -3.68 and a beta of 0.44.

TriSalus Life Sciences (NASDAQ:TLSI) last issued its earnings results on Thursday, August 6th. The company reported ($0.16) EPS for the quarter, hitting analysts’ consensus estimates of ($0.16). The firm had revenue of $11.41 million for the quarter, compared to analysts’ expectations of $10.27 million. Sell-side analysts forecast that TriSalus Life Sciences will post -0.31 EPS for the current year.

Institutional Investors Weigh In On TriSalus Life Sciences

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Cura Wealth Advisors LLC purchased a new stake in TriSalus Life Sciences in the second quarter valued at approximately $36,000. HighMark Wealth Management LLC acquired a new position in TriSalus Life Sciences during the 4th quarter worth about $75,000. Renaissance Technologies LLC purchased a new position in TriSalus Life Sciences during the 1st quarter valued at about $124,000. Deutsche Bank AG purchased a new position in TriSalus Life Sciences during the 2nd quarter valued at about $221,000. Finally, Sei Investments Co. acquired a new position in TriSalus Life Sciences in the 1st quarter valued at about $275,000. 2.58% of the stock is owned by hedge funds and other institutional investors.

About TriSalus Life Sciences

TriSalus Life Sciences is an oncology company focused on developing technologies and therapies for patients with liver and pancreatic tumors. The company’s approach combines investigational immunotherapies with drug-delivery technologies intended to improve treatment access to solid tumors, which can be difficult to reach through conventional systemic administration.

TriSalus is best known for its Pressure-Enabled Drug Delivery (PEDD) platform, which is designed to deliver medicines directly into tumors or their surrounding blood vessels by using controlled pressure.